Showing results (151-160 of 301) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibodyRhona Stein, Serengulam V Govindan, Marianne Hayes, et al.
Advances in Experimental Medicine and Biology|October 18, 2003
Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materialsJulia A O'Hara, Rosalyn D Blumenthal, Oleg Y Grinberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 16, 2006
Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic originManuel J Koppe, Wim J G Oyen, Robert P Bleichrodt, et al.
Cancer Research|January 25, 2003
A universal pretargeting system for cancer detection and therapy using bispecific antibodyRobert M Sharkey, William J McBride, Habibe Karacay, et al.
Gynecologic Oncology Reports|July 7, 2018
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case reportChanhee Han, Stefania Bellone, Peter E Schwartz, et al.
EJNMMI Research|September 6, 2019
A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancerFortuné M K Elekonawo, Susanne Lütje, Gerben M Franssen, et al.
Bioconjugate Chemistry|June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complexWilliam J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
Blood|January 27, 2010
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathwaysRhona Stein, Pankaj Gupta, Xiaochuan Chen, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Molecular Pharmaceutics|November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drugSerengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Pageof 31